Newport Strategies

Newport Strategies was a leading provider of competitive intelligence and strategic decision-support systems for the global generic pharmaceutical industry. The company's flagship product, Newport Horizon, provided detailed data on drug patents, regulatory filings, and market opportunities to help companies identify and develop generic drug candidates. By offering insights into API manufacturers and global market dynamics, the firm became an essential resource for portfolio managers in the generics sector. It was acquired by Thomson Reuters in 2004 and its offerings were subsequently integrated into Clarivate's life sciences portfolio. Today, the Newport name continues as a specialized intelligence platform within Clarivate.